Fig. 1From: The efficacy of a cyclin dependent kinase 9 (CDK9) inhibitor, FIT039, on verruca vulgaris: study protocol for a randomized controlled trialA flowchart of the study design. Eligible subjects will be randomly divided into two groups (intervention and control) and will be followed for 6 weeksBack to article page